Abstract
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clinical trials for coronary artery disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1020-33 |
| Number of pages | 14 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 9 |
| Issue number | 9 |
| Publication status | Published - 1 Sept 2008 |